KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Total Debt (2017 - 2025)

Novartis Ag's Total Debt history spans 9 years, with the latest figure at $28.7 billion for Q4 2025.

  • For Q4 2025, Total Debt fell 2.94% year-over-year to $28.7 billion; the TTM value through Dec 2025 reached $28.7 billion, down 2.94%, while the annual FY2025 figure was $28.7 billion, 2.94% down from the prior year.
  • Total Debt for Q4 2025 was $28.7 billion at Novartis Ag, down from $29.6 billion in the prior quarter.
  • Across five years, Total Debt topped out at $29.6 billion in Q4 2024 and bottomed at $19.1 billion in Q4 2023.
  • The 5-year median for Total Debt is $25.5 billion (2021), against an average of $24.8 billion.
  • The largest annual shift saw Total Debt decreased 29.19% in 2021 before it soared 55.29% in 2024.
  • A 5-year view of Total Debt shows it stood at $25.5 billion in 2021, then dropped by 17.3% to $21.1 billion in 2022, then dropped by 9.7% to $19.1 billion in 2023, then skyrocketed by 55.29% to $29.6 billion in 2024, then dropped by 2.94% to $28.7 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Total Debt are $28.7 billion (Q4 2025), $29.6 billion (Q4 2024), and $19.1 billion (Q4 2023).